{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-217039","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.594066+00:00","generated_at":"2026-06-11T06:28:57.679457+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Coya appoints former Bayer Pharma CEO Dieter Weinand to board of directors","bullets":["Board expands to 6 members; Weinand named Class I director effective August 18, 2023.","Weinand granted option to buy 10,000 shares at $3.43, vesting on one-year anniversary.","He joins audit and nominating/governance committees, committees expanded to 4 members.","Weinand is former CEO and Chairman of Bayer Pharma AG; current chairman of Replimune and others.","Coya expects to leverage his 25+ years of pharma experience for strategic guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-217039","json":"https://secwatch.observer/filing/0001193125-23-217039.json","markdown":"https://secwatch.observer/filing/0001193125-23-217039.md","text":"https://secwatch.observer/filing/0001193125-23-217039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523217039/0001193125-23-217039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523217039/d535860d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:28:57.679457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1729610085","claim":"Dieter Weinand was appointed as Class I Director at Coya Therapeutics, Inc..","evidence_excerpt":"On August 18, 2023, the board of directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) increased the size of the Board to six directors from five, and appointed Dieter Weinand as a Class I director to fill the newly created vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312523217039/0001193125-23-217039-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}